Literature DB >> 1326579

Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides.

D J Schendel1, C Reinhardt, P J Nelson, B Maget, L Pullen, G W Bornkamm, A Steinle.   

Abstract

Human CTL have been isolated that show self-restricted recognition of autologous lymphoblastoid cell lines and allorecognition. The lymphoblastoid cell line ligand most likely used a peptide that is expressed in EBV-bearing cells when the virus enters the lytic cycle. This peptide is presented to CD8+ CTL by HLA-Cw7 molecules. The allogeneic ligand recognized on non-EBV-infected cells is composed of a class I glycoprotein and a naturally selected self-peptide. In previous studies we demonstrated that this ligand is determined by two MHC-linked genes: one gene encodes the allogeneic class I molecule whereas the other controls the self-peptide. Despite the use of different peptides and different class I molecules, seemingly equivalent structures are formed that enable these two ligands to function as antigenic mimics of each other. CTL with the same patterns of dual specificity could be isolated from four unrelated donors, indicating that HLA-Cw7 is frequently involved in self-restricted recognition of EBV-harboring cells. Such CTL could help not only to contain lytic virus during a primary infection but also may be maintained life-long to eliminate cells in which reactivated virus appears.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326579

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Epstein-Barr virus in the pathogenesis of oral cancers.

Authors:  J T Guidry; C E Birdwell; R S Scott
Journal:  Oral Dis       Date:  2017-04-18       Impact factor: 3.511

2.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 3.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  HLA-C revisited. Ten years of change.

Authors:  C S Falk; D J Schendel
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  Alloimmune T cells in transplantation.

Authors:  Susan DeWolf; Megan Sykes
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

6.  Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.

Authors:  C Bogedain; H Wolf; S Modrow; G Stuber; W Jilg
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.

Authors:  M Colonna; G Borsellino; M Falco; G B Ferrara; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  Allele-specific peptide ligand motifs of HLA-C molecules.

Authors:  K Falk; O Rötzschke; B Grahovac; D Schendel; S Stevanović; V Gnau; G Jung; J L Strominger; H G Rammensee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 9.  Immunopathogenic mechanisms in psoriasis.

Authors:  J E Gudjonsson; A Johnston; H Sigmundsdottir; H Valdimarsson
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone.

Authors:  R P Johnson; A Trocha; T M Buchanan; B D Walker
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.